Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed EBITDA for 7 consecutive years, with -$38.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 35.57% to -$38.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$190.5 million through Dec 2025, up 25.78% year-over-year, with the annual reading at -$190.5 million for FY2025, 25.78% up from the prior year.
  • EBITDA hit -$38.8 million in Q4 2025 for Allogene Therapeutics, up from -$41.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.1 million in Q4 2021 to a low of -$96.0 million in Q1 2023.
  • Historically, EBITDA has averaged -$64.9 million across 5 years, with a median of -$65.8 million in 2024.
  • Biggest five-year swings in EBITDA: skyrocketed 98.46% in 2021 and later crashed 4424.39% in 2022.
  • Year by year, EBITDA stood at -$2.1 million in 2021, then plummeted by 4424.39% to -$94.2 million in 2022, then increased by 10.53% to -$84.3 million in 2023, then rose by 28.62% to -$60.2 million in 2024, then surged by 35.57% to -$38.8 million in 2025.
  • Business Quant data shows EBITDA for ALLO at -$38.8 million in Q4 2025, -$41.1 million in Q3 2025, and -$51.0 million in Q2 2025.